Latest Proteomics News

Page 1 of 4
Waters delivered a stronger-than-expected third quarter, lifting every component of its 2026 guidance while organic growth accelerated across instruments, consumables and reagents. The company also acquired MOBILion Systems to extend its mass spectrometry technology into proteomics.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.
Victor Sage
Victor Sage
23 Oct 2026
Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.
Ada Torres
Ada Torres
14 Sept 2026
Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
Ada Torres
13 Aug 2026
Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.
Ada Torres
Ada Torres
27 July 2026
Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.
Ada Torres
Ada Torres
22 July 2026
Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.
Ada Torres
Ada Torres
8 July 2026
Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.
Ada Torres
Ada Torres
7 May 2026
Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.
Ada Torres
Ada Torres
28 Apr 2026
Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.
Ada Torres
Ada Torres
17 Apr 2026

Browse the archive

Full archive